Taken together, DYRK1A and RCAN1 can act synergistically to block NFAT-dependent transcription, suggesting that the reduced NFAT activity resulting from the 1.5-fold overexpression of DYRK1A and RCAN1 could be the basis of many features of Down syndrome [28], [31]. Here, RCAN1 is linked to Down syndrome.